Vericel Corporation (NASDAQ:VCEL) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.
At its Annual Meeting of Shareholders held on May 3, 2017 (the
Annual Meeting), the shareholders of Vericel Corporation, a
Michigan corporation (the Company) voted on the following
matters, which are described in detail in the Companys Proxy
Statement filed with the U.S. Securities and Exchange Commission
on March 20, 2017: (i) to elect each of Robert L. Zerbe, Alan L.
Rubino, Heidi Hagen, Steven Gilman, Kevin McLaughlin, Paul Wotton
and Dominick C. Colangelo as a director of the Company to serve
for a one-year term expiring at the Companys 2018 annual meeting
of shareholders and until his or her successor has been elected
and qualified (Proposal 1), (ii) to ratify the appointment of
PricewaterhouseCoopers LLP as the Companys independent registered
public accounting firm for the fiscal year ending December 31,
2017 (Proposal 2), (iii) to approve the 2017 Omnibus Incentive
Plan (Proposal 3), and (iv) to approve, on an advisory basis, the
compensation of the named executive officers of the Company
(Proposal 4).
The Companys shareholders approved the nominees recommended for
election in Proposal 1 at the Annual Meeting.
Shareholders voted for directors as follows:
|
Nominee |
|
For |
|
Abstain/Withheld |
|
Broker Non-Votes |
|
|
Robert L. Zerbe |
13,014,457 |
323,577 |
14,336,871 |
||||
|
Alan L. Rubino |
13,025,486 |
312,548 |
14,336,871 |
||||
|
Heidi Hagen |
13,038,712 |
299,322 |
14,336,871 |
||||
|
Steven Gilman |
11,386,885 |
1,951,149 |
14,336,871 |
||||
|
Kevin McLaughlin |
13,022,458 |
315,576 |
14,336,871 |
||||
|
Paul Wotton |
13,021,811 |
316,223 |
14,336,871 |
||||
|
Dominick C. Colangelo |
12,998,323 |
339,711 |
14,336,871 |
The Companys shareholders approved Proposal 2. The votes cast at
the Annual Meeting were as follows:
|
Votes For |
|
Votes Against |
|
Abstentions |
|||
|
26,602,355 |
954,770 |
117,780 |
The Companys shareholders approved Proposal 3. The votes cast at
the Annual Meeting were as follows:
|
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
|
|
12,468,246 |
742,533 |
127,255 |
14,336,871 |
The Companys shareholders approved Proposal 4. The votes cast at
the Annual Meeting were as follows:
|
Votes For |
|
Votes Against |
|
Abstentions |
|
Broker Non-Votes |
|
|
12,489,064 |
713,403 |
135,567 |
14,336,871 |
About Vericel Corporation (NASDAQ:VCEL)
Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy. Vericel Corporation (NASDAQ:VCEL) Recent Trading Information
Vericel Corporation (NASDAQ:VCEL) closed its last trading session down -0.03 at 2.60 with 119,770 shares trading hands.